Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Mar;28(3):171–178. doi: 10.1007/BF00204985

In vivo efficacy of monoclonal antibody — drug conjugates of three different subisotypes which bind the human tumor — associated antigen defined by the KS1/4 monoclonal antibody

James J Starling 1,✉, Ronald S Maciak 1, N Ann Hinson 1, Cynthia L Nichols 1, Stephen L Briggs 1, Bennett C Laguzza 1
PMCID: PMC11038250  PMID: 2784353

Abstract

A panel of three hybridomas has been isolated each of which secretes a single species of monoclonal antibody (MoAb) directed against the KS1/4 tumor-associated antigen originally described by Varki et al. (Cancer Res 44:681, 1984). These MoAbs were designated L1-(IgG2b), L2-(IgG1), and L4-(IgG2a) KS. Binding specificity, immunoprecipitation, and competitive binding analyses indicated that these MoAbs each recognize the same epitope of the KS1/4 antigen. The immunoprecipitation studies indicated that the MoAbs recognized a major antigenic component of 42 kDa and a minor component of 35 kDa. The L-KS antibodies were evaluated as MoAb-drug conjugates against a variety of human tumor targets grown in vivo as nude mouse xenografts. The MoAb-drug conjugates were constructed using protein-A-purified MoAbs conjugated to 4-desacetyl-vinblastine-3-carboxhydrazide. Efficacy was determined using various dosing protocols on 2–14 day established tumors of lung, pharynx, colon, and skin origin. Control experiments included the use of dual-flank antigen-positive and negative tumors, free MoAbs, free drug, and mixtures of MoAbs and drug. These studies indicated that significant tumor growth supression and actual tumor regression could be achieved by the MoAb — vinca conjugates and that this activity was antigen-mediated. The drug conjugates were more efficacious than free drug or free MoAbs administered either singly or in combination with each other.

Keywords: Free Drug, Mouse Xenograft, Competitive Binding, Actual Tumor, Negative Tumor

References

  • 1.Ackers GK. Analytical gel chromatography of proteins. Adv Protein Chem. 1970;24:343. doi: 10.1016/s0065-3233(08)60245-4. [DOI] [PubMed] [Google Scholar]
  • 2.Baldwin RW. Monoclonal antibody targeting of anticancer agents: Muhlbock memorial lecture. Eur J Clin Oncol. 1985;21:1281. doi: 10.1016/0277-5379(85)90304-9. [DOI] [PubMed] [Google Scholar]
  • 3.Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA. 1982;79:1245. doi: 10.1073/pnas.79.4.1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chee DO, Boddie AL, Jr., Roth JA, Holmes EC, Morton DL. Production for melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res. 1976;36:1503. [PubMed] [Google Scholar]
  • 5.Frankel AE, Houston LL, Issell BF, Fathman G. Prospects for immunotoxin therapy in cancer. Annu Rev Med. 1986;37:125. doi: 10.1146/annurev.me.37.020186.001013. [DOI] [PubMed] [Google Scholar]
  • 6.Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbot BJ (1972) Cancer Chemother Rep 3:1
  • 7.Goding JW. Antibody production by hybridomas. J Immunol Methods. 1980;39:285. doi: 10.1016/0022-1759(80)90230-6. [DOI] [PubMed] [Google Scholar]
  • 8.Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci. 1982;79:4761. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol. 1985;92:105. doi: 10.1016/0008-8749(85)90068-1. [DOI] [PubMed] [Google Scholar]
  • 10.Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vahdhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Johnson DA, Laguzza BC. Antitumor xenograft activity with a conjugate of a vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res. 1987;47:3118. [PubMed] [Google Scholar]
  • 12.Johnson IS, Spearman ME, Todd GC, Zimmerman JL, Bumol TF. Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: preclinical pharmacology and toxicology studies. Cancer Treat Rev. 1987;14:193. doi: 10.1016/0305-7372(87)90007-7. [DOI] [PubMed] [Google Scholar]
  • 13.Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 14.Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature. 1970;227:680. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 15.Levy R, Miller RA. Tumor therapy with monoclonal antibodies. Fed Proc. 1983;42:2650. [PubMed] [Google Scholar]
  • 16.Markwell MAK. A new solid-stage reagent to iodinate proteins. Anal Biochem. 1982;125:427. doi: 10.1016/0003-2697(82)90025-2. [DOI] [PubMed] [Google Scholar]
  • 17.Moldofsky PJ, Powe J, Hammond ND. Tumor detection using radiolabeled monoclonal antibodies. CRC Crit Rev Clin Lab Sci. 1987;25:313. doi: 10.3109/10408368709105887. [DOI] [PubMed] [Google Scholar]
  • 18.Moon TD, Vessella RL, Lange PH. Monoclonal antibodies in urology. J Urol. 1983;130:584. doi: 10.1016/s0022-5347(17)51319-1. [DOI] [PubMed] [Google Scholar]
  • 19.Noonan KD. An analysis of concanavalin A-mediated agglutination in tow Chinese hamster ovary sublcones whose surface phenotypes respond to maintenance in medium supplemented with dibutryl cyclic AMP. V. Biochemical composition of the plasma membrane. Biochim Biophys Acta. 1979;551:22. doi: 10.1016/0005-2736(79)90350-x. [DOI] [PubMed] [Google Scholar]
  • 20.Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG, Ferm M, Schoenberger CS, Farrell M, Kimball E, Sherwin SA. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol. 1984;2:1235. doi: 10.1200/JCO.1984.2.11.1235. [DOI] [PubMed] [Google Scholar]
  • 21.Reisfeld RA, Cheresh DA. Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy. Cancer Surveys. 1985;4:271. [PubMed] [Google Scholar]
  • 22.Sears HF, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod. 1984;3:138. [PubMed] [Google Scholar]
  • 23.Sinkovics JG, Dreesman GR. Monoclonal antibodies of hybridomas. Rev Infect Dis. 1983;5:9. doi: 10.1093/clinids/5.1.9. [DOI] [PubMed] [Google Scholar]
  • 24.Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, Kawahata RT, Stoudemire JB, Fradkin LB, Bautista EE, Scannon PJ. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-Ricin A chain immunotoxin. Cancer Res. 1987;47:1717. [PubMed] [Google Scholar]
  • 25.Starling JJ, Sieg SM, Beckett ML, Schellhammer PF, Ladaga LE, Wright GL., Jr. Monoclonal antibodies to human prostate and bladder tumor-associated antigens. Cancer Res. 1982;42:3084. [PubMed] [Google Scholar]
  • 26.Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 1983;221:865. doi: 10.1126/science.6879183. [DOI] [PubMed] [Google Scholar]
  • 27.Taggart RT, Samloff IM. Stable antibody-producing murine hybridomas. Science. 1983;219:1228. doi: 10.1126/science.6402815. [DOI] [PubMed] [Google Scholar]
  • 28.Takahashi T, Yamaguchi T, Kazuya K, Suzuyama H, Honda M, Yokota T, Hitoshi K, Takahashi M, Hashimoto Y. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinona. Cancer. 1988;61:881. doi: 10.1002/1097-0142(19880301)61:5<881::aid-cncr2820610505>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  • 29.Teh JG, Stacker SA, Thompson CH, McKenzie IFC. The diagnosis of human tumours with monoclonal antibodies. Cancer Surv. 1985;4:149. [PubMed] [Google Scholar]
  • 30.Varki NM, Reisfeld RA, Walker LE. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 1984;44:681. [PubMed] [Google Scholar]
  • 31.Varki NM, Reisfeld RA, Walker LE. Monoclonal antibodies and cancer therapy. New York: Alan R. Liss; 1985. Effect of monoclonal antibody-drug conjugates of the in vivo growth of human tumors established in nude mice; p. 207. [Google Scholar]
  • 32.Wright GL. Monoclonal antibodies and cancer. New York and Basel: Marcel Dekker Inc.; 1984. Application of monoclonal antibodies to the study of human cancer; p. 1. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES